NIHNATIONAL CANCER INSTITUTE

The SIK2 Inhibitor GRN-300 Enhances PARP Inhibitor Sensitivity and Cytotoxic T-Cell Function in Ovarian Cancer

Active

Institution: UNIVERSITY OF TX MD ANDERSON CAN CTR, TX
Principal investigator: Robert C Bast
Funding: $177K
Duration: 2023–2028

Open portfolio

Moonbase score

Still being scored

LOADING MOONBASE SCORE

NATIONAL CANCER INSTITUTEP50ZCA1-RPRB-H(M1)Senhancesovariancytotoxicovarian cancersensitivityparpt-cellinhibitor

Questions for UNIVERSITY OF TX MD ANDERSON CAN CTR

Answered by the team behind this research.

No questions yet. Sign in to ask the first one

Same researchers, same institution, same topic, scored first.

NIH · University of TX MD Anderson Can CtrNot yet scored
The SIK2 Inhibitor GRN-300 Enhances PARP Inhibitor Sensitivity and Cytotoxic T-Cell Function in Ovarian Cancer
Robert C Bast · $273K · 2023–2028
NIH · University of TX MD Anderson Can CtrNot yet scored
Developmental Research Program
Robert C Bast · $76K · 2023–2028
NIH · University of TX MD Anderson Can CtrNot yet scored
Career Enhancement Program
Robert C Bast · $76K · 2023–2028
NIH · University of TX MD Anderson Can CtrNot yet scored
DIRAS3 disrupts K-RAS clustering and signaling, enhancing autophagy and response to autophagy inhibition
Robert C Bast · $1.1M · 2022–2027
NIH · University of TX MD Anderson Can CtrNot yet scored
MD Anderson Cancer Center EDRN- Clinical Validation Center for Early Detection of Ovarian Cancer with a multiple marker algorithm
Robert C Bast · $1.1M · 2016–2028
NIH · University of TX MD Anderson Can Ctr49
Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients
Khandan Keyomarsi · $428K · 2020–2026
NIH · University of TX MD Anderson Can Ctr47
Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)
Michael Andreeff · $461K · 2019–2027
NIH · University of TX MD Anderson Can Ctr46
Modulation of intracellular lipid access by ATGL determines ferroptosis sensitivity in castration-resistant prostate cancer
Pham Hong Anh Cao · $39K · 2025–2027
NIH · University of TX MD Anderson Can Ctr46
Metabolic basis of ARID1A-mutated ovarian cancer
Rugang Zhang · $494K · 2022–2027
NIH · University of TX MD Anderson Can Ctr44
Machine learning for identifying antigen-antibody interactions from massive sequencing data
Junzhou Huang · $686K · 2025–2030
NIH · University of TX MD Anderson Can Ctr43
Unraveling the functional contribution of extracellular vesicles in pancreatic cancer
Kathleen Mcandrews · $192K · 2024–2027
NIH · Dana-Farber Cancer InstNot yet scored
Randomized trial of REVITALIZE: A telehealth intervention to reduce fatigue interference among adults with advanced ovarian cancer on PARP inhibitors
Joanna J Arch · $686K · 2024–2029
NIH · University of Colorado DenverNot yet scored
Evaluation of combination CLK/DYRK (Cirtuvivint) inhibition with PARP inhibition (Olaparib) in BRCA/HRD platinum resistant ovarian cancer
Bradley Corr · $400K · 2024–2029
NIH · University of TX MD Anderson Can CtrNot yet scored
Targeting p300 to Overcome PARP inhibitor resistance induced by acidic tumor microenvironment
Rugang Zhang · $388K · 2023–2028
NIH · Medical University of South CarolinaNot yet scored
Preclinical Development of the Novel Inhibitor of Apoptosis Proteins S2/IAPinh for Cancer Therapy
William G Hawkins · $181K · 2022–2027
NIH · San Diego State UniversityNot yet scored
Alternative NF-kB activation in post-chemotherapy setting to elucidate novel mechanisms of ovarian cancer relapse
Carrie Danielle House · $346K · 2022–2027
NIH · San Diego State UniversityNot yet scored
Alternative NF-kB activation in post-chemotherapy setting to elucidate novel mechanisms of ovarian cancer relapse
Carrie Danielle House · $87K · 2022–2027

Questions for UNIVERSITY OF TX MD ANDERSON CAN CTR

Related grants